Studies a new clot-dissolving drug in people with acute stroke
Collects data on staphylokinase, a clot-dissolving drug, in adults with acute stroke.
Plain-language title generated from the registry record
Registry title: Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice
Key facts
- Where
- Saint Petersburg, RussiaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT05697575, who can take part
Where in Russia
- St. Petersburg Research Institute of Emergency Medicine named after I.I. JanelidzeSaint Petersburg, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Society for Neurosonology and Cerebral Circulation
- Trial code
- NCT05697575
- Record updated
- 13 April 2026
- Original description
The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.Read full original descriptionShow less
Non-interventional Observational Study to Evaluate the Efficacy and Safety of Non-immune Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice
The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.
Inclusion: Age 18-85 ; Diagnosis of acute ischemic stroke eligible for thrombolytic therapy; Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed.
Exclusion: Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase; The presence of a contraindication to thrombolytic therapy of ischemic stroke; Pregnancy or lactation.